NASDAQ · AADI

Aadi Bioscience, Inc.

Healthcare · Biotechnology

$2.05▼ 2.38% ($0.05)at close

As of 4:00 PM ET

52-week

$1.21$3.81

Market cap

$94.89M

P/E

-2.51

Volume

62.61K

Shares outstanding

46.29M

What the market price implies · Reverse DCF

Historical revenue grew by 58.93%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$2.05

Estimated value / share

Unavailable

Base scenario

USD · FY 2025

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 0% · Ending margin 0% · Discount rate 7.7%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Mar 18, 2025, 8:00 PM UTC
Financial statement period: FY 2025
Data refreshed: Sep 11, 2026, 2:44 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -3.3%Revenue (TTM): -100%FCF (TTM): 129.68%P/S: 75th pct

What changed

The stock fell 3.3% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 129.68% over the trailing twelve months.

What the market seems to be pricing

The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway.

CEODavid J. Lennon

SectorHealthcare

IndustryBiotechnology

Employees53

IPO dateFeb 16, 2018

https://aadibio.com

Market multiples

Forward P/E—

EV/EBITDA-10.76

Enterprise value$1.23B

Stock splits

Aug 27, 2021↓ Reverse

Every 15 shares became 1

-93%

Aug 18, 2021↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth—

Gross margin0%▼88.4ppvs FY2024

Operating margin0%▼1341.5ppvs FY2024

ROE-44.98%▼23.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$1.63▼20.49%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Mar 12, 2026

Q2 FY26 · EPS est — · Revenue est —

View